If you typed George Clinical (Emerald Clinical) into a search box, you are probably building a CRO shortlist. This article uses only what George Clinical (Emerald Clinical) publishes (georgesclinical.com/therapeutic-expertise/medical-devices-cro · emeraldclinical.com) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It is a practitioner comparison, not a teardown.
What George Clinical (Emerald Clinical) publishes
George Clinical, which came out of Sydney's The George Institute, rebranded as Emerald Clinical in 2025. Its medical device page covers feasibility, pilot, Class II/III pivotal and post-market studies. It is a full-service CRO with 500+ people, 40 locations and 70 geographies, strongest in renal, cardiovascular and oncology late-phase work.
George Clinical (Emerald Clinical) vs bioaccess®
| Dimension | George Clinical (Emerald Clinical) | bioaccess® |
|---|---|---|
| Core focus | APAC-origin full-service CRO, late-phase strength | First-in-human and early feasibility studies for medical devices |
| Geography | Australia | Latin America, since 2010 |
| Device FIH track record | No named device first-in-human study found on the public pages reviewed | Published case studies on bioaccessla.com |
| After the trial | See provider site | Live multi-country sanitary registration and in-country holder service |
Where each one fits
If the device program is a large pivotal or post-market study across Asia-Pacific, George / Emerald is a capable choice.
If the job is a first-in-human or early feasibility study for a medical device, bioaccess® is a specialist built for exactly that, running device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including George Clinical (Emerald Clinical), for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan and how the data was used in an FDA file.
Australia sells real country features: the CTN scheme, English-language ethics and, for eligible companies, the R&D tax incentive. Those are country features, not George Clinical (Emerald Clinical) features. The country math is on bioaccess® vs Australia, and the established Australian device EFS boutique is covered in Mobius Medical vs bioaccess®.
Ready to compare a proposal? Request a first-in-human study proposal.
Competitor facts from the George Clinical (Emerald Clinical) public pages linked above and public announcements, reviewed for bioaccess® competitive research (Aug–Oct 2026). Claims are theirs. No invented sponsors, prices or contacts.
Leave a Reply